Did This Top Biotech Stock Just Go On Sale?

A decision to sell more shares to the public this week didn't help bluebird bio's (NASDAQ: BLUE) sagging share price this year. The equity offering dilutes investors and throws cold water on hopes that an acquisition will happen soon. Nevertheless, bluebird bio remains on track to file for FDA approval of two gene therapy drugs in the next year, and trials for these drugs so far suggest they could be big successes.

Topics:  blue sagging   fda   dna   sciences nasdaq   gild and novartis nyse   nvs chimeric   t-cell   yescarta   kymriah   source   images    nasdaq   biotech   stock   sale   year   therapies   bluebird   gene   optimism   investors   drugs   
BING NEWS:
  • Is Ginkgo Bioworks Holdings Stock a Buy?
    Ginkgo expects to add 100 customer projects this year. And the biotech company anticipates its revenue will total between $170 million and $190 million. By comparison, in 2023, the company's revenue ...
    05/18/2024 - 7:37 am | View Link
  • Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
    InvestorPlace - Stock Market News, Stock Advice & Trading Tips With innovation, millions of retiring baby boomers, demand for better care, ...
    05/16/2024 - 11:15 pm | View Link
  • Attention Biotech Investors
    RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, ...
    05/16/2024 - 7:21 am | View Link
  • Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
    As the earnings come to an end in the ongoing reporting cycle, the focus shifts to pipeline and regulatory updates. Collaborations and agreements continue to be in the spotlight as pharma and biotech ...
    05/16/2024 - 5:46 am | View Link
  • Is Bluebird Bio Stock a Buy?
    Bluebird Bio has three approved gene-editing therapies: Zynteglo, Skysona, and Lyfgenia. The most important of this trio, and the latest to earn approval (it did so in December), is Lyfgenia, which ...
    05/16/2024 - 2:22 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News